The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global human immunodeficiency virus (HIV) emergency provides “hope” to ...

The U.S. Senate has opened debate on a $9 billion rescission bill to claw back foreign aid and other funding not aligned with ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...